Are MIC Injections FDA-Approved for Weight Loss
The successful molecule, named Liraglutide, entered clinical testing in 2000 as an injectable drug for the treatment of diabetes
More recently, dual GLP-1/GIP agonists like tirzepatide have shown even greater weight loss potential, with some patients achieving a 20% reduction in body weight
For many, using a brand-name product even at a lower dose or less frequent dosing may be safer than using non-approved compounded versions
The seven drugs that are currently considered GLP-1 receptor agonists include: Dulaglutide (Trulicity) Tirzepatide (Mounjaro, Zepbound) Exenatide extended-release (Bydureon) Exenatide (Byetta) Semaglutide injection (Ozempic, Wegovy) Semaglutide tablet (Rybelsus) Liraglutide (Victoza, Saxenda) Lixisenatide (Adlyxin) If all of these drugs influence GLP-1 in similar ways, what makes each of them unique